@article{34650309491344f7b0637485501cc061,
title = "Breath volatile organic compounds and inflammatory markers in adult asthma patients: Negative results from the ALLIANCE cohort",
author = "Olaf Holz and Benjamin Waschki and Henrik Watz and Anne Kirsten and Mustafa Abdo and Frauke Pedersen and Markus Weckmann and Oliver Fuchs and Dittrich, {Anna Maria} and Gesine Hansen and Kopp, {Matthias V.} and {Von Mutius}, Erika and Rabe, {Klaus F.} and Hohlfeld, {Jens M.} and Thomas Bahmer",
note = "Funding Information: Conflict of interest: O. Holz has nothing to disclose. B. Waschki has nothing to disclose. H. Watz has nothing to disclose. A. Kirsten has nothing to disclose. M. Abdo has nothing to disclose. F. Pedersen has nothing to disclose. M. Weckmann has nothing to disclose. O. Fuchs has nothing to disclose. A-M. Dittrich has nothing to disclose. G. Hansen reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study. M.V. Kopp reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study; personal fees for lectures and consultancy from ALK-Abello, Allergopharma, Chiesi, Meda, Novartis Pharma, Vertex, Abbvie and Infectopharm, grants from Allergopharma and Vertex, outside the submitted work. E. von Mutius reports grants from the German Federal Ministry for Education and Research (BMBF) for the German Center for Lung Research (DZL), during the conduct of the study; authorship fees from Springer-Verlag GmbH, Georg Thieme Verlag and Elsevier Ltd, personal fees for consultancy from HiPP GmbH & Co. KG, OM Pharma SA and Peptinnovate Ltd, personal fees for lectures from Boehringer Ingelheim International GmbH, outside the submitted work; and has a patent LU101064, “Barn dust extract for the prevention and treatment of diseases” pending, a patent EP2361632, “Specific environmental bacteria for the protection from and/or the treatment of allergic, chronic inflammatory and/or autoimmune disorders” with royalties paid to ProtectImmun GmbH, a patent number EP 1411977, “Composition containing bacterial antigens used for the prophylaxis and the treatment of allergic diseases” licensed to ProtectImmun GmbH, a patent EP1637147, “Stable dust extract for allergy protection” licensed to ProtectImmun GmbH, and a patent EP 1964570, “Pharmaceutical compound to protect against allergies and inflammatory diseases” licensed to ProtectImmun GmbH. K.F. Rabe reports grants and personal fees from Boehringer Ingelheim and AstraZeneca, personal fees from Novartis, Sanofi, Regeneron, Roche and Chiesi Pharmaceuticals outside the submitted work. J.M. Hohlfeld reports grants from German Ministry for Education and Research (BMBF; grant DZL 2016-2020/82DZL002A2), during the conduct of the study; personal fees for consultancy from Boehringer Ingelheim and Merck & Co., Inc., personal fees for lectures from Novartis and HAL, grants from AstraZeneca AB, Novartis, Janssen Pharmaceutica NV, ALK, Boehringer Ingelheim, LETI, GlaxoSmithKline, Sanofi-Aventis, Astellas Pharma and Allergopharma, outside the submitted work. T. Bahmer reports grants from BMBF (unrestricted research grant for the German Center for Lung Research, DZL), during the conduct of the study; personal fees lectures and consultancy, and compensation of travel expenses from AstraZeneca, GlaxoSmithKline, Novartis and Roche, outside the submitted work. Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = feb,
day = "1",
doi = "10.1183/13993003.02127-2020",
language = "English",
volume = "57",
journal = "European Respiratory Journal",
issn = "0903-1936",
number = "2",
}
